SEYLTX

Dr. Bonuccelli has held a number of leadership positions focusing on the late-stage clinical development of large and small molecule programs in the respiratory and inflammation therapeutic areas. She served as Chief Medical Officer of Bellus Health from 2019 until its acquisition by GSK in 2023. Prior to joining Bellus, Dr. Bonuccelli spent more than four years serving as US Medical Affairs Respiratory Therapeutic Area Head for GSK. In this capacity, she oversaw all medical support activities for the company’s portfolio of respiratory treatments. She had previously had a 20-year tenure with AstraZeneca, where she held a number of roles, including Global Medicines Clinical Vice President for the Inflammation, Neuroscience, & Respiratory Therapeutic Area, and Therapy Area Clinical Vice President, Respiratory and Inflammation. In these positions, she had oversight for all aspects of late-stage clinical development, including product strategy and creation of Phase III-IV study protocols and design for inhaled, oral and biologic products including Symbicort and Fasenra. She was also responsible for designing and delivering brand lifecycle management opportunities, creating long-term portfolio strategies and managing medical and scientific staff.

Dr. Bonuccelli earned her MD, and was an Intern, Resident, Research Fellow and Clinical Fellow, at Johns Hopkins University in Baltimore, Maryland. She has authored more than 30 publications and abstracts, has been a board member of several prominent boards and has been licensed in three states.